The hallmarks of cancer and the radiation oncologist: Updating the 5Rs of radiobiology

Clinical Oncology

Volumn 25, Issue 10, 2013, Pages 569-577

  Good, J S ^a   Harrington, K J ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Radiobiology; Radiosensitivity; Redistribution; Reoxygenation; Repair; Repopulation

Indexed keywords

BEVACIZUMAB; METFORMIN; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL FATE; CELL MEMBRANE; DNA DAMAGE; ENERGY METABOLISM; GAIN OF FUNCTION MUTATION; GENOMIC INSTABILITY; HUMAN; NATURAL KILLER CELL; ONCOGENE; ONCOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RADIATION RESPONSE; RADIOBIOLOGY; RECTUM CANCER; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

RADIOBIOLOGY; RADIOSENSITIVITY; REDISTRIBUTION; REOXYGENATION; REPAIR; REPOPULATION;

HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIATION TOLERANCE;

EID: 84883301484     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.06.009     Document Type: Article

References (87)

1. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137.
2. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12(2):127-136.
3. Tree A.C., Khoo V.S., Eeles R.A., et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14(1):28-37.
4. Harrington K.J., Jankowska P., Hingorani M. Molecular biology for the radiation oncologist: the 5Rs of radiobiology meet the hallmarks of cancer. Clin Oncol 2007, 19(8):561-571.
5. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
6. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
7. Loeb L.A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 2011, 11:450-457.
8. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21(3):309-322.
9. Yarden Y., Pines G. The ERRB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012, 12(8):553-563.
10. Chen D.J., Nirodi C.S. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007, 13(22):6555-6560.
11. Krause M., Ostermann G., Petersen C., et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 2005, 76(2):162-167.
12. Lee H.L., Chung T.S., Ting L.L., et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 2012, 7:181.
13. Butler J.M., Kobayashi H., Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010, 10(2):138-146.
14. Hellevik T., Pettersen I., Berg V., et al. Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol 2012, 7:59.
15. Roder F., Coppe J.P., Patil C.K., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11(8):973-979.
16. Luo J., Solimini N., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837.
17. Senra J.M., Telfer B.A., Cherry K.E., et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011, 10(10):1949-1958.
18. Chalmers A.J., Lakshman M., Chan N., Bristow R.G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010, 20(4):274-281.
19. Bouquet F., Pai A., Pilones K.A., et al. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells invitro and promotes tumor control by radiation invivo. Clin Cancer Res 2011, 17(21):1-12.
20. Hardee M.E., Marciscano A.E., Medina-Ramirex C.M., et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can abolished by inhibiting transforming growth factor-β. Cancer Res 2012, 72(16):1-11.
21. Flechsig P., Dadrich M., Bickelhaupt S., et al. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 2012, 18(13):3616-3627.
22. Andarawewa K.L., Paupert J., Pal A., Barcellos-Hoff M.H. New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol 2007, 83(11-12):803-811.
23. Vance S., Liu E., Zhao L., et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 2011, 15(10):4321-4329.
24. Apel A., Herr I., Schwarz H., Rodermann H.P., Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68(5):1485-1494.
25. Lauber K., Munoz L.E., Berens C., et al. Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy. Radiat Oncol 2011, 6:176.
26. + T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
27. Park H.J., Griffin R.J., Hui S., Levitt S.H., Song C.W. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012, 177:311-327.
28. Li Z., Rich J.N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Micro Immunol 2010, 345:21-30.
29. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8(7):545-554.
30. Semenza G.L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 2012, 9:534-543.
31. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockade of the vascular endothelial growth factor stress response increases the antitumour effects of ionizing radiation. Cancer Res 1999, 59:3374-3378.
32. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumour response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300(5622):1155-1159.
33. Chung Y.L., Jian J.J., Cheng S.H., et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12(9):2706-2715.
34. Janssens G.O., Rademakers S.E., Terhaard C.H., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. JClin Oncol 2012, 30(15):1777-1783.
35. Hoskin P.J., Rojas A.M., Bentzen S.M., Saunders M.I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. JClin Oncol 2010, 28(33):4912-4918.
36. Overgaard J., Eriksen J.G., Nordsmark M., et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6(10):757-764.
37. Rischin D., Peters L.J., O'Sullivan B., et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. JClin Oncol 2010, 28(18):2989-2995.
38. Hicks K.O., Siim B.G., Jaiswal J.K., et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res 2010, 16:4946-4957.
39. Hunter F.W., Wang J., Patel R., et al. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with hypoxia-activated prodrugs. Biochem Pharmacol 2012, 83:574-585.
40. Dipetrillo T., Pricolo V., Lagares-Garcia J., et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012, 82(1):124-129.
41. Kleibeuker E.A., Griffioen A.W., Verheul H.M., Slotman B.J., Thijssen V.L. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 2012, 15(3):173-182.
42. Drissi R., Wu J., Hu Y., Bockhold C.A., Dome J.S. Telomere shortening alters the kinetics of the DNA damage response after ionizing radiation in human cells. Cancer Prev Res 2011, 4(12):1973-1981.
43. Wong K.K., Chang S., Weiler S.R., et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 2000, 26(1):85-88.
44. Ram R., Uziel O., Eldan O., et al. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 2009, 15(3):914-923.
45. Buseman C.M., Wright W.E., Shay J.W. Is telomerase a viable target in cancer?. Mutat Res 2012, 730(1-2):90-97.
46. Kuroda S., Fujiwara T., Shirakawa Y., et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010, 70(22):9339-9348.
47. Wu X., Smavadati S., Nordfjäll K., et al. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochim Biophys Acta 2012, 1823(12):2130-2135.
48. Marlan C.O., Cho S.K., McEllin B.M., et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010, 16(1):154-163.
49. Merle P., Evrard B., Petitjean A., et al. Telomere targeting with a new G4 ligand enhances radiation-induced killing of human glioblastoma cells. Mol Cancer Ther 2011, 10(10):1784-1795.
50. Harless W.W. Cancer treatments transform residual cancer cell phenotype. Cancer Cell Int 2011, 11:1.
51. Zhou Y.C., Liu J.Y., Li J., et al. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys 2011, 81(5):1530-1537.
52. Wang M., Hada M., Saha J., et al. Protons sensitize epithelial cells to mesenchymal transition. PLoS One 2012, 7(7):e41249.
53. Sun S.P., Jin Y.N., Yang H.P., Wei Y., Dong Z. Serum transforming growth factor-beta1 level reflects disease status in patients with esophageal carcinoma after radiotherapy. World J Gastroenterol 2007, 13(39):5267-5272.
54. Kawamoto A., Yokoe T., Tanaka K., et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep 2012, 27(1):51-57.
55. Stone H.B., Peters L.J., Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. JNatl Cancer Inst 1979, 63:1229-1235.
56. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Ann Rev Immunol 2004, 22:329-360.
57. Vasto S., Carruba G., Lio D., et al. Inflammation, ageing and cancer. Mech Ageing Dev 2009, 130:40-45.
58. Vertuani S., Triulzi C., Roos A.K., et al. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumour recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009, 58:653-664.
59. Fisher D.T., Chen Q., Skitzki J.J., et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. JClin Invest 2011, 121(10):3846-3859.
60. Cavallo F., de Giovanni C., Nanni P., Forni G., Lollini P.L. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011, 60:319-326.
61. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
62. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. NEngl J Med 2012, 366(10):925-931.
63. Burnette B., Fu Y.X., Weichselbaum R.R. The confluence of radiotherapy and immunotherapy. Front Oncol 2012, 2:143.
64. Schaue D., Ratikan J.A., Iwamoto K.S., McBride W.H. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012, 83(4):1306-1310.
65. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
66. Van der Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
67. Christofk H.R., Vander Heiden M.G., Harris M.H., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452(7184):230-233.
68. Robey R.B., Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009, 19:25-31.
69. Sattler U.G., Mueller-Klieser W. The anti-oxidant capacity of tumour glycolysis. Int J Radiat Biol 2009, 85(11):963-971.
70. Hirschhaeuser F., Sattler U.K., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011, 71(22):6921-6925.
71. Quennet V., Yaromina A., Zips D., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006, 81(2):130-135.
72. Semenza G.L. Tumor metabolism: cancer cells give and take lactate. JClin Invest 2008, 118:3835-3837.
73. Noto H., Goto A., Tsujimoto T., Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012, 7(3):e33411.
74. Song C.W., Lee H., Dings R.P., et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012, 2:362.
75. Ben Sahra I., Laurent K., Giuliano S., et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010, 70(6):2465-2475.
76. Skinner H.D., Crane C.H., Garrett C.R., et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2013, 2(1):99-107.
77. Lin X., Zhang F., Bradbury C.M., et al. 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003, 63(12):3413-3417.
78. Singh D., Banerji A.K., Dwarakanath B.S., et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005, 181:507-514.
79. Abdelwahab M.G., Fenton K.E., Preul M.C., et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 2012, 7(5):e36197.
80. [accessed 21.02.13]. http://clinicaltrials.gov/show/NCT01419587.
81. Safdie F., Brandhorst S., Wei M., et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One 2012, 7(9):e44603.
82. Bortfield T., Jeraj R. The physical basis and future of radiation therapy. Br J Radiol 2011, 84(1002):485-498.
83. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEngl J Med 2012, 366(10):883-892.
84. de Palma M., Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol 2012, 6:111-127.
85. Eschrich S., Zhang H., Zhao H., et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009, 75(2):497-505.
86. Oh J.H., Wong H.P., Wang X., Deasy J.O. Abioinformatics filtering strategy for identifying radiation response biomarker candidates. PLoS One 2012, 7(6):e38870.
87. Zietman A. The future of radiation oncology: the evolution, diversification, and survival of the specialty. Semin Radiat Oncol 2008, 18(3):207-213.